Welcome to Idorsia

Idorsia announces
financial results for the
first nine months of 2020

Positive results in second
pivotal study with
daridorexant for
patients with
insomnia

Our 2019 report
consists of three
books

There’s more to Idorsia
than meets the eye!

Read the interview with
our CEO & CSO to get to
the bottom of the story...

Our key assets have
the potential to
transform treatment in
the target indications...

The purpose of Idorsia is to discover, develop and bring more, innovative medicines to patients.

Idorsia’s success depends on its people.

Idorsia's development compounds target a number of different diseases.

23 Nov 2020	Idorsia announces positive results of the two Japanese registration studies with clazosentan
27 Oct 2020	Idorsia announces financial results for the first nine months of 2020
21 Oct 2020	Idorsia successfully completes capital increase with gross proceeds of CHF 535.5 million

Event	When
Full-Year 2020 Financial Results reporting*	February 4, 2021
First Quarter 2021 Financial Results reporting*	April 22, 2021
Annual General Meeting of Shareholders	May 12, 2021
Half-Year 2021 Financial Results reporting*	July 27, 2021

*We will be in a silent period for 10 days ahead of the financial reporting.

IDIA SIX Swiss Exchange

At 17:20:00 CET

27.18 CHF

-0.28 (-1.02 %)

Idorsia Pharmaceuticals Ltd

Hegenheimermattweg 91

4123 Allschwil

Switzerland